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Abstract
Background: Renal replacement therapy (RRT) is growing by 10 % per year in Russia, but pre-dialysis care which
can retard CKD progression and delay the start of RRT remains limited. We evaluate the effect of Essential Amino
Acids and Keto-analogues (EAA/KA) on CKD progression.
Methods: The effect of low protein diet (LPD), supplemented by EAA/KA, on GFR slope changes between first and
second treatment period (five sequential visits per period) in 96 patients withs CKD Stage 3B-5 was compared to
GFR slope changes in the control group of 96 patients, randomly selected from matched (by gender, age, diagnosis
and CKD Stage) cohort of 320 patients from the city Registry. The mean baseline eGFR was 23 ± 9 ml/min/
1.73 m2; 29 % had CKD3B, 45 % - CKD4, 26 % - CKD5.
Results: The rate of eGFR decline changed from −2.71 ± 2.38 to −2.01 ± 2.26 ml/min/1.73 m2 per year in the treatment
group and from −2.18 ± 2.01 to −2.04 ± 2.18 ml/min/1.73 m2 per year in the control group. Only in the treatment group
the difference was significant (p = 0.04 and p = 0.6). Standardized effect size for intervention was significant in treatment
group: −0.3 (of pooled SD), 95 % CI −0.58 ÷ −0.02 and non-significant in control group: −0.07 (−0.35 ÷ +0.22). The
univariate and multivariate analysis of EAA/KA therapy effect demonstrated that it was probably more effective in
patients of older age, with higher time-averaged proteinuria (PU), lower phosphate level, in patients with glomerular v.
interstitial diseases, and in females. Only the latter factor was significant at pre-specified level (<0.05).
Conclusions: LPD combined with EAA/KA supplementation lead to the decrease of the CKD progression both in
well-designed clinical study and in real nephrology practice in wide variety diseases and settings. Registry data can be
helpful to reveal patients with optimal chances for beneficial effect of LPD supplemented by EAA/KA.
Trial registration: ISRCTN28190556 06/05/2016.
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Background
Renal replacement therapy (RRT) is growing rapidly in
Russia with average 10 % increase per year [1]. That re-
flects the increasing number of new dialysis centers
(mainly private, erected by international dialysis networks)
in substantially changing conditions, including implemen-
tation of diagnosis-related groups (DRG) system for reim-
bursement [2]. Prevalence of RRT remains rather low,
however it grew from 56 per million population (pmp)
in 1998 to 246 pmp in 2013 (Russian Dialysis Society
Registry data [1]) and 299 pmp in 2015 (marketing
data). It means that dialysis treatment becoming now
available for majority of patients in most regions of
Russia, the more so as the average incidence rate remains
rather low – 51 pmp, presumably due to younger popula-
tion, lower prevalence of diabetes mellitus, lower and later
CKD revealing. Nevertheless, some regions, like Saint
Petersburg [3] (70 pmp) look similar to the neighboring
countries like Finland (89 pmp) and Estonia (63 pmp).
The proportion of patients with functioning graft
among those on RRT decreased slowly from 25 % in
1998 to 19 % in 2013, while the proportion of HD patients
increased from 70 % in 1998 to 75 % in 2013. The propor-
tion of PD patients remains stable low - 5–7 %. Thus low-
protein diet (LPD) actually is no more considered as the
method to ensure survival while waiting period for RRT,
but the issue of quality of life, retardation of CKD pro-
gression and delaying “the health start” of dialysis.
Requirements for dietary protein intake in the non-
nephrotic CKD patients without inflammatory conditions
or other catabolic states appear to be equal to the require-
ments of healthy individuals: average 0.6 g/kg/day of unse-
lected or mixed biological value [4].
Regimens with less than 0.6 g/kg/day protein intake are
often difficult for application, unless ‘non-proteic’ (com-
mercially available) carbohydrates are applied [5] to main-
tain enough calorie consumption, however this products
are not easily available everywhere for every patient and
different approaches are acceptable [6].
The rate of CKD progression, evaluated by decrease
of estimated GFR (CKD-EPI equation) depends on nu-
merous factors and can be delayed by nephroprotective
therapy, in particular – by nutrition therapy. We assessed
the effect of LPD supplemented by keto-analogues (EAA/
KA) therapy on the rate of eGFR decline in the real prac-
tice, using prospectively collected data obtained from St.-
Petersburg city nephrology Registry.
Methods
All patients with CKD Stage 3–5, referred to city neph-
rology center, are offered dietary counseling by experi-
enced nephrologist. LPD is routinely recommended to
all patients at high risk for CKD progression after evalu-
ation the CKD stage, GFR decline rate and excluding the
symptoms and signs of protein-energy wasting based on
physician’s judgment and labs: albumin <3.8 or <3.5 g/dl
for diabetics, phosphate < 0.8 mmol/l; in some cases an-
thropometric data (skinfold, calculated muscle section
area) and additional criteria (absolute lymphocyte num-
ber, transferrin level) are used. Patients with very low life
expectancy are excluded from low protein diet interven-
tions. Detailed nutritional manual for patients with CKD
is available for patients [7]. Several examples of daily
LPD (0.6 g/kg/day) and VLPD (0.3 g/kg/day) adopted
for Russian traditions and food habits are presented in
the Appendix. Patients can get information about ex-
changeability of some products, about forbidden and
allowed products.
Patients were initially prescribed a standard LPD (0.60 g
protein/kg body weight/day). For patients who demon-
strated treatment compliance to LPD, low-phosphate
diet, nephroprotective therapy (iACE or ARB), and
have moderate to severe proteinuria (PU) – defined as
PU >1.0 g/day, the additional restriction of dietary protein,
supplemented by EAA/KA may be considered. Patients
are provided with EAA/KA (prescribed dose - one pill per
5 kg body weight) by the special social drugstore, supplied
from budgetary funded source, so-called “additional medi-
cinal providing”. About 200 patients simultaneously re-
ceive EAA/KA in St.-Petersburg from this source. For
logistics, clinical and personal reasons not all patients have
received EAA/KA without substantial interruptions and
long enough to evaluate the changes in GFR slope.
Patients, comprising study group were selected from
St-Petersburg CKD registry (which includes more than
6000 patients with CKD3+ as we described in details
earlier [3]) according following criteria: confirmed mod-
erate GFR decline rate (see below); patient’s compliance
to diet and pharmacological therapy; and prolonged his-
tory of regular EAA/KA therapy according to the data
from special database, recording patient’s’ visits to drug-
store for EAA/KA supplied by budgetary funded source
(≥10 consecutive visits with pre-defined for each CKD
stage frequency). Patients, who received commercially
available EAA/KA were not included in the study as we
could not ensure adequate treatment regimens. In 96 pa-
tients with CKD stages 3B-5 the progressive decrease of
eGFR was confirmed by previous monitoring during >
6 months. GFR decrease rate was evaluated as linear re-
gression coefficient of CKD-EPI GFR versus visit date
with the number of visit ≥ 4 (median 5; IR 4 ÷ 7). Pa-
tients with rapid CKD progression (more than 10 ml/
min/1.73 m2 per year) were excluded from analysis. The
mean baseline eGFR was 23 ± 9 ml/min/1.73 m2; 29 % of
patients had CKD3B, 45 % - CKD4, 26 % - CKD5. We
intend to maintain all patients on LPD with protein intake
0.8–0.6 g/day. Patients receiving EAA/KA therapy are ad-
vised to keep to LPD with protein intake < 0.6 g/day
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(evaluated by 3-day diaries). Protein-free products are
included to supply energy with negligible load of phos-
phorus, sodium, potassium and nitrogen [8].
Evaluation of treatment compliance for the diet is more
qualitative than quantitative. We request our patients to
provide food diaries at least for three days between visits
at every visit. The most concerned patients provide diaries
for all period between visits. During the visit nephrologist
can discuss the patient’s menu while labs are processed, as
unfortunately patients have no regular access to dietician
consult. LPD have to provide at least 30 kcal/kg/day of
energy, lower intake of calories is considered in those
with body mass index (BMI) >28 kg/m2. Phosphate binders
(calcium carbonate or calcium acetate or aluminum hy-
droxide) are prescribed according to the guidelines in
order to maintain serum phosphate within the normal
range (0.81–1.45 mmol/l) [9]. As a nephroprotective
and antihypertensive therapy 64 % of patients received
ACEi, 16 % - ARB, 24 % - CCB, 11 % - beta-blockers.
Patients keeping diet undergo full clinical evaluation,
including dietary counseling with special emphasis to
diet adherence at least quarterly for CKD3, every 2 months
for CKD4, and monthly for CKD5. At each visit, blood
pressure (BP), body weight, serum urea, creatinine,
sodium, potassium, phosphate, calcium, total protein,
albumin, and hemoglobin are measured; transferrin sat-
uration and ferritin are measured quarterly, total chol-
esterol, triglycerides – twice a year. In patients with
more often visits, additional visit data was averaged
with those of the closest visit.
Statistical analysis
Continuous variables were presented as the mean ±
standard deviation (SD) – for normally distributed vari-
ables - or as median (25 ÷ 75 percentiles) for others.
Categorical data were presented as percent of frequency.
The comparisons between normally distributed variables
were performed by Student test, between other con-
tinuous variables – by Mann–Whitney test, between
categorical parameters – by χ2 test with P-values <0,05
for significance. The relationship between continuous
variables was investigated by the Pearson correlation
coefficients and P-values. The size effect was evaluated
by raw paired difference and by paired difference stan-
dardized by standard deviation and corresponding 95 %
confidence interval.
Results
Evaluation of effect in treatment group
The effects of LPD supplemented by EAA/KA were eval-
uated during period of 10 routine visits to nephrologist
following the EAA/KA prescription. The mean dose of
EAA/KA was 11 ± 2 pills per day (0.8 ± 0.1 pills/5 kg
BW – 20 % lower than prescribed). The slope of the
eGFR decrease was calculated by regression model for
first 5 visits and for following 5 visits. These data were
compared to the data for 96 patients, randomly selected
from matched group (by gender, age, diagnosis, protein-
uria and CKD stage) of 320 patients from the registry.
Table 1 shows comparison of baseline parameters in
two groups.
The only statistically significant (but not clinically sig-
nificant) was the difference in serum sodium level. Table 2
shows that the comorbidity in treatment and control
groups was similar.
Table 3 shows the changes of eGFR during first and
second periods of the study in treatment group vs con-
trol group. The duration of the first and second five-visit
period was 8.6 ± 1.6 and 8.4 ± 1.9 months for treatment
group and 8.9 ± 2.0 and 8.6 ± 2.0 months for control
group (all differences are non-significant, p > 0.05).
The rate of eGFR decline changed from −2.71 ± 2.38
to −2.01 ± 2.26 ml/min/1.73 m2 per year in the treatment
group and from −2.18 ± 2.01 to −2.04 ± 2.18 ml/min/
1.73 m2 per year in the control group. While decrease of
the eGFR decline was noticed in both treatment (−0.70
(0.04 ÷ 1.36; ml/min per year) and control (−0.14 (−0.46 ÷
0.74;) groups, only in the treatment group this difference
was significant (p = 0.04 and p = 0.6). The difference in
raw effect size was −0.56 ± 0.10 ml/min/1.73 m2 per year,
(95 % confidential interval −0.75 ÷ −0.37), standardized
effect size for intervention was significant in treatment
group: −0.3 (of pooled SD), 95 % CI −0.58 ÷ −0.02 and
non-significant in control group: −0.07 (−0.35 ÷ +0.22).
The search for pro- and con- factors for EAA/KA effect
Table 4 demonstrates the results of univariate and multi-
variate analysis of EAA/KA therapy effect in association
with some potential confounding parameters. For cate-
gorical (binary) variables the comparison of the changes
(from first to second period) of GFR slope are presented
for two levels of binary variable. Table 3 also shows the re-
sults of multi-variate analysis of EAA/KA therapy. This
intervention was probably more effective in patients of
older age, with greater time-averaged PU, lower phosphate
level, in glomerular v. intestinal diseases, and in females
(p for exclusion from regression model 0.10). Only the
latter factor was significant at pre-specified level (<0.05).
Although beneficial effect of therapy was not signifi-
cantly linked to PU level in uni- and multivariate ana-
lysis, the slope of eGFR decline was not surprisingly
directly associated with PU.
As PTH target ranges were determined at different
levels in CKD3 (<70 pg/ml), CKD4 (<85 pg/ml) and
CKD5 (non-dialysis - <110 pg/ml) in Russian National
CKD-MBD guidelines, we evaluated the percentage of
patients with PTH above these levels: 23/96 in treatment
group and 26/96 in control group (p = 0.6); the mean
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baseline PTH levels were 69 ± 32 v. 63 ± 37 pg/ml (p = 0.4).
The slope of PTH elevation was not significant in both
groups and did not differ between the groups (2 ± 11 pg/
ml/year, p = 0.1).
The difference in raw effect size was slightly more
expressed in women (−0.58 ± 0.11 v. –0.54 ± 0.09 ml/min/
1.73 m2 per year; p = 0.06) and in patients with glomerular
diseases compared to interstitial diseases (−0.60 ± 0.15
v. –0.54 ± 0.14 ml/min/1.73 m2 per year; p < 0.01).
During the study period 26 patients from treatment
group entered the more advanced CKD stage, in 62 pa-
tients CKD stage did not change, and 8 patients showed
slow but stable improvement of kidney function; corre-
sponding subgroups in control group consisted of 32,
57 and 7 patients respectively (for difference in χ2-test
p > 0.2).
Discussion
Comparing the changes of GFR slope from first to
second period in the intervention (EAA/KA therapy)
group and control group we demonstrated that LPD,
supplemented by EAA/KA, could decrease the rate of
CKD progression. Five-visit interval of evaluation for
eGFR slope was rather long and different factors could
interfere the CKD progression, however five visits data is
necessary to calculate eGFR precisely enough to be reli-
ably compared in various settings. Possibly the first period
(as comparator) should be shorter to exclude the already
achieved effect of EAA/KA therapy that mitigate the
difference.
Chang et al. demonstrated similar results, in their
study EAA/KA was added for 6 months to previously
prescribed LPD (0.6 g/kg/day of proteins for 6 months)
in 120 patients with CKD3-4. The decline of GFR slopes
during the LPD + EAA/KA period was significantly
lower than during the LPD alone period. Multivariate
analysis revealed that responsiveness to LPD + EAA/KA
was independently related to diabetes (p = 0.006) and
high serum albumin levels (p = 0.011) in the LPD alone
period [10]. The potentially influencing factors in our
study (Table 3) were different, that may reflect the dif-
ferences in the patient’s population. Di Iorio et al. dem-
onstrated the influence of phosphate level in the study
of 99 proteinuric CKD patients, transferred from LPD
to very low protein diet (VLPD), which resulted in the
halving of proteinuria, but the anti-proteinuric effect
was attenuated by high level of phosphate [11].
In earlier (and smaller) prospective randomized study
Teplan et al. demonstrated that LPD (0.6 g/kg/day of
proteins) supplemented with EAA/KA led to lower
Table 1 Baseline characteristic of patients in treatment and control group
Treatment group Control group p
Number of patients 96 96
Diabetes mellitus type II 12/96 (13 %) 14/96 (14 %) p = 0.8
Polycystic kidney disease 6/96 (6 %) 8/96 (8 %) p = 0.6
Hypertension 23 (24 %) 20 (21 %) p = 0.6
Male/female 40/56 (42 %) 44/52 (46 %) p = 0.6
Age 54 ± 15 57 ± 13 p = 0.14
eGFR (CKD-EPI), ml/min/1.73 m2 23 ± 9 25 ± 11 p = 0.17
CKD stage 3B/4/5 28/43/25 (29 %/45 %/26 %) 33/37/26 (34 %/39 %/27 %) p = 0.6
Albumin, g/dl 4.1 ± 0.5 4.2 ± 0.4 p = 0.13
Calcium, mmol/l 2.28 ± 0.16 2.26 ± 0.14 p = 0.4
Phosphate, mmol/l 1,27 ± 0,26 1,21 ± 0,24 p = 0.10
Sodium, mmol/l 140 ± 3 141 ± 3 p = 0.02
Cholesterol, mmol/l 5.8 ± 1.2 5.5 ± 1.0 p = 0.06
Triglycerides, mmol/ 2.06 ± 0.98 1.85 ± 1.11 p = 0.19
Hemoglobin, g/dl 12.4 ± 1.4 12.2 ± 1.3 p = 0.3
Serum Fe, μmol/l 13 ± 5 12 ± 4 p = 0.13
CRP, mg/dl 0.1 ÷ 0.6 0.2 ÷ 0.8 p = 0.13
Mean proteinuria, g/day 1.18 ÷ 2.56 1.24 ÷ 2.42 p = 0.06
Maximal proteinuria, g/day 1.49 ÷ 4.94 1.56 ÷ 5.72 p = 0.11
Number of patients with hypertension (>140/90 mmHg) 31/96 (32 %) 34/96 (35 %) p = 0.5
Systolic blood pressure 137 ± 20 139 ± 22 p = 0.5
Diastolic blood pressure 83 ± 12 81 ± 11 p = 0.2
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decrease of kidney function in patients with baseline
GFR 22–36 ml/min, compared to LPD alone, although
the number of follow-up visits was very small (once in
6 months) [12].
Despite VLPDs are usually considered more effective
in postponing dialysis in compliant patients, only minority
(as low as 14 %) of patients can follow it properly [13],
which was demonstrated by the data from the assessment
period of randomized study with 3-year period of enroll-
ment. After such strict selection VLPD group showed
57 % lower GFR decline rate (−4.9 v. -2.1 ml/min per
year). Interestingly, we found very similar results in our
supplemented LPD group (−2.01 ± 2.26). In above men-
tioned publication standard deviation for GFR decline
rate was not presented, so it is not possible to compare
standardized size effect of interventions.
Recent meta-analysis (7 randomized controlled trials,
one cross-over trial, and one non-randomized concurrent
control trial, all of them published before April 2015)
results indicated that comparing to normal protein diet,
LPD or VLPD supplemented with keto-analogues (SLPD/
SVLPD) were able to significantly prevent the deterio-
ration of kidney function, defined by eGFR (P < 0.001);
hyperparathyroidism (P = 0.04); hypertension (P < 0.01);
and hyperphosphatemia (P < 0.001) – thus could delay
the progression of CKD effectively without causing
malnutrition [14].
Supplementation with EAA/KA is not strictly needed
for vegan diets with protein intake 0.6 g/kg/day, but if
applied, EAA/KA ensure the balanced intake of different
aminoacids. If EAA/KA are not used, different types of
products (e.g. legumes and cereals) should be combined
Table 3 The size effect of intervention: difference in eGFR decline rate between first and second period of study in treatment group
vs control group
eGFR decline rate Standardized effect size








ml/min/1.73 m2 per year
Treatment group −2.71 ± 2.38 −2.01 ± 2.26 0.30 0.15 0.02÷0.58
Control group −2.18 ± 2.01 −2.04 ± 2.18 0.07 0.14 −0.22÷0.35
Difference p = 0.10 p = 0.93 p < 0.001
Table 2 Charlson comorbidity index in treatment and control groups (M ± SD or number of cases)
Treatment group Control group p
Charlson comorbidity index 4,91 ± 1,67 5,09 ± 1,58 0,59
Myocardial infarction 8 9 0,73
Congestive heart failure 24 28 0,37
Peripheral disease 43 36 0,14
Cerebrovascular disease 28 24 0,35
Dementia 3 6 0,21
Chronic pulmonary disease 9 13 0,23
Connective tissue disease 2 5 0,17
Peptic ulcer disease 13 19 0,12
Mild liver disease 11 18 0,07
Diabetes without end-organ damage 10 11 0,75
Hemiplegia 4 2 0,15
Moderate or severe renal disease 96 96 –
Diabetes with end-organ damage 2 3 0,56
Tumor without metastasis 4 3 0,61
Leukemia 1 1 –
Lymphoma 1 1 –
Moderate or severe liver disease 3 4 0,61
Metastatic solid tumor 0 0 –
AIDS 0 0 –
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at every meal [15], that can be burdensome for some
patients. Supplementation permits also a simplified ap-
proach, which just exclude animal products, but allows
a free choice of vegetables, fruits, legumes and cereals
[5, 6].
Additional approach to enhance the compliance to
LPD - an occasional unrestricted meal (one to three
times per week) - is practiced by at least two Italian
groups of researchers [5], in elderly patients in particular
[16]: Usually we do not practice broadly this approach as
we consider that some aspects of Russian mentality will
prompt our patients to subsequent diet liberalization.
Nevertheless, we believe this approach could be useful
for some patients.
As special protein-free food is virtually available in Russia
(with one historical precursor – protein-free bread in
1980s), but the choice is limited (as some of them are
very salty, and others are rather expensive or contain
substantial amount of phosphate). More or less accept-
able is mainly pasta of stretch origin, or mixtures for
homemade bakery. Protein-free food is partly available
for free to CKD patients only in Italy [17].
The MDRD Study and a secondary analysis of this
study did not suggest a clear benefit from SVLPD as
compared with the 0.60 g protein/kg/d, although there
was a trend towards slower progression of kidney failure
with the SVLPD. However, SVLPD used in the MDRD
Study probably was not ideal because the keto acid/EAA
supplements contained rather large amount of trypto-
phan, which could generate more nephrotoxic metabo-
lites, particularly indoxyl sulfate [4]. Hence, it is possible
that alternative keto acid/EAA supplements will be more
effective in slowing of the CKD progression.
Presently only two of mixtures/combinations of amino
acids and keto acids, both of which are marketed by the
same company, are available: Alfa Kappa (in Italy) or
Ketosteril (globally) [6].
Potential drawbacks come down when the vegetarian
diet is associated with too restricted protein intake and/or
insufficient energy intake, justifying an early and regular
follow-up by a nephrologist to avoid malnutrition [15].
Unfortunately, due to lack of reimbursement for this
service, we presently have no access to concealing our
patients by certified dietitian on regular basis.
Although we have no rigorous confirmation for
benefit of supplementation of LPD by EAA/KA in
RCT, we have to keep in mind that as soon as the ef-
ficacy of intervention strongly depends on the pa-
tient’s active participation, RCT may be inappropriate
tool because the random allocation per se can reduce
the effect of the intervention [17]. The alternative ap-
proach is the search for the factors and conditions, which
could make the intervention more efficient. Controlled
observation studies are one of important step on this way.
Various LPDs cannot only influence the CKD progression,
but also impact on dialysis outcomes, when patients finally
achieve CKD5D stage. In this area, the RCT’s are more
unfeasible.
Bellizzi et all showed, that mortality risk in dialysis period
was 0.59 (p < 0.001) after SVLPD pre-dialysis treatment,
compared to propensity score matched group of unse-
lected control, but risk for patients, previously treated
Table 4 Reducing effect of EAA/KA on GFR slope decrease: the results of uni-variate analysis, categorical variable comparison and
variables in final multi-variate model
Uni-variate analysis Final model of multi-variate analysisb
Variable Unstandardized B p 95 % CI for B Unstandardized B p 95 % CI for B
Age (per 10 year) 0.023 0.08 −0.004 ÷ 0.05 0.021 0.06 −0.002 ÷ 0.04
PU mean (per 1 g/day) −0.061 0.08 −0.13 ÷ 0.09 −0.065 0.06 −0.14 ÷ 0.005
PU max (per 1 g/day) −0.023 0.38 −0.004 ÷ 0.05 – – –
Albumin (per 0.1 g/dl) −0.061 0.21 −0.04 ÷ 0.16 – – –
Phosphate (per 0.1 mmol/l) 0.015 0.18 −0.008 ÷ 0.04 0.016 0.08 −0.003 ÷ 0.03
Hb (per 1 g/dl) 0.018 0.32 −0.02 ÷ 0.06 – – –
ln CRP (per 0.1 mg/dla) −0.039 0.14 −0.09 ÷ 0.15 – – –
Categorical variable comparisons Categorical variable in equation
Glom. v. interst. −0.082 ± 0.035 0.06 −0.059 ± 0.044 −0.016 0.06 −0.003 ÷ 0.03
Female v. male −0.079 ± 0.025 0.11 −0.066 ± 0.024 −0.013 0.03 −0.003 ÷ − 0.001
DM v. non-DM −0.072 ± 0.021 0.50 −0.069 ± 0.023 – – –
CI confidence interval, PU proteinuria, g/day, mean averaged for study period, max maximum per study period, Hb hemoglobin, CRP C-reactive protein, glom.
glomerular diseases, interst. interstitial diseases, DM diabetes mellitus
aBefore ln-transformation
bp for exclusion from model 0.10
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with LPD was not different from SVLPD group (RR =
0.84; p = 0.496).In subgroup analysis females aged <70,
without diabetes and cardiovascular diseases, had more
pronounced treatment effect [18].
In recent study from Taiwan, Markov model showed
that the group with EAA/KA early initiation gained
higher QALYs with lower cost when compared to the
watchful-waiting group. Analysis of sensitivity indicated
that early EAA/KA initiation (eGFR 17–29 mL/min/
1.73 m2) would be the preferred cost-effective option, if
achieved relative reduction of eGFR decline, associated
with LPD plus EAA/KA, is > 4 % [19]. Due to insuffi-
cient power our study we could not differentiate the size
effect between different CKD stages, but could show that
the LPD with EAA/KA supplementation resulted in 7 %
relative reduction of eGFR decline rate (compared with
control group) – thus, could be cost-effective.
Moderately restricted LPDs may be adapted to virtually
any cuisine and should be tailored to the patients’ pref-
erences, while VLPDs usually require trained, compliant
patients; a broader offer of diet options may lead to
more widespread use of LPDs [17].
Limitations
The patient selection for LPD (<0.6 g/kg/day) supple-
mented by EAA/KA in our study was not random and
could contain selection bias (patients with better com-
pliance to diet can have better compliance to other
nephroprotective strategies, such as antihypertensive
and anti-RAAS therapy, sodium restriction, and optimal
glycemic control. On the other hand, the matched control
group recruited from 320 similar patients was rather close
to the treatment group. These confounding factors were
taken in consideration in multiple regression analysis. Of
note, patients with pre-dialysis CKD were not regularly
evaluated for acid-base balance, and rarely received bicar-
bonates; this information was not included into analysis.
Evaluation of compliance to diet was more qualitative
than quantitative, but such approach may be considered
as acceptable [6]. The number of patients, included into
analysis, was relatively small as it was restricted to those
who received EAA/KA supplied from budgetary funded
source; on the other hand, the amount of EAA/KA
gained in drugstore was available as a surrogate measure
for received doses in parallel with patients’ diary.
Conclusions
Low protein diet combined with EAA/KA supplementa-
tion lead to the decrease of the CKD progression both in
well-designed clinical study and in real nephrologist
practice in wide variety diseases and settings. Registry
data can reveal patients with optimal chance for benefi-
cial effect of LPD supplemented by EAA/KA.
Appendix




Breakfast 1. Bread, butter, honey, coffee.
(mixed bread 40 g, white bread 40 g, butter 20,
honey 30 g, cream 10 ml, sugar 10 g).
Breakfast 2. Applesauce.
(apple 100 g, sugar 10 g, cinnamon steak)
Dinner. Quenelle, cauliflower, potato; chocolate jelly.
(pork 50 g, onion 20 g, bread 30 g, cauliflower
150 g, vegetable oil 10 g, corn starch 5 g, nutmeg,
cream 10 ml, potato 200 g; cream 30 ml, water
100 ml, sugar 10 g, cocoa 5 g, gelatin 2 g).
Lunch. Bread, butter, marmalade, coffee or tea.
(mixed bread 20 g, butter 10 g, marmalade 20 g,
sugar 10 g).
Supper. Bread, butter, black pudding, celery salad, tea.
(mixed bread 80 g, butter 20 g, black pudding 30 g;
celery 150 g, apple 50 g, vegetable oil 10 g, vinegar,
onion, ginger, sugar 10 g).
Energy 2250 kcal/9410 kJ; protein – 41 g, fat – 108 g,
carbohydrates – 267 g, sodium – 0.74 g, potassium –
2.7 g, calcium – 0.27 g, phosphorus – 0.8 g.
Day 2
Breakfast 1. Bread, butter, marmalade, smoked sausage,
coffee.
(mixed bread 40 g, white bread 40 g, marmalade
20 g, smoked sausage 30 g, butter 20, cream 10 ml,
sugar 10 g).
Breakfast 2. Bread, lard, onion, tea.
(mixed bread 40 g, lard 15 g, onion 5 g,,sugar 10 g).
Dinner. Potato mash, boiled egg, sweet and sour sauce,
salad.
(potato 250 g, cream 30 ml, butter 10 g, vegetable oil
10 g, 1 egg, lard 10 g, corn starch 10 g, onion 5 g, bay
leaf, pepper; red beet – 100 g, vinegar, caraway-seeds
onion 5 g, vegetable oil 5 g, sugar 10 g).
Lunch. Bread, butter, marmalade, coffee.
(white bread 40 g, butter 10 g, marmalade 20 g,
sugar 10 g).
Supper. Fried potato, vegetable aspic, tea.
(potato 200 g, butter 10 g, lard 10 g, onion 5 g,
boiled carrot 100 g, green peas 30 g, cauliflower
30 g, water 120 g, onion 30 g, bay leaf, clove,
mustard 5 g, vinegar).
Energy 2260 kcal/9460 kJ; protein – 40 g, fat – 107 g,
carbohydrates – 274 g, sodium – 1 g, potassium –
3.37 g, calcium – 0.24 g, phosphorus – 0.75 g.
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Day 3
Breakfast 1. Bread, butter, marmalade, coffee.
(mixed bread 40 g, white bread 40 g, marmalade
30 g,, butter 20, cream 10 ml, sugar 10 g).
Breakfast 2. Fruit salad.
(apple 50 g, cherry 50 g, lemon juice 10 g, sugar 15 g).
Dinner. Chicken with sauce, rice, salad, currant pudding
with cream.
(chicken breast 60 g, mushroom 20 ml, onion 20 g,
apple 50 g, vegetable oil 10 g, rice 50 g, butter 10 g,
pet Sai 80 g, cream 10 g, vinegar; red currant juice–
100 ml, water 50 ml, sugar 10 g, corn starch 10 g,
cream 10 g).
Lunch. stick-like biscuits 20 g, butter, marmalade, coffee.
(white bread 40 g, butter 10 g, honey 20 g, sugar
10 g, cream 10 g.).
Supper. Scrambled eggs with tomato, herb butter, tea.
(1 small egg, tomato 30 g, butter 10 g, lard 10 g,
onion 5 g, mixed bread 80 g, butter 20, sugar 10 g).
Energy 2279 kcal/9450 kJ; protein – 40 g, fat – 106 g,
carbohydrates – 275 g, sodium – 1.3 g, potassium –
055 g, calcium – 0.19 g, phosphorus – 0.67 g.
VLPD (0.3 g/kg/day)
Day 1
Breakfast 1. Bread, butter, honey, marmalade, coffee.
(low-protein bread 80 g, butter 10, marmalade 20 g,
honey 10 g, cream 10 ml, sugar 10 g).
Breakfast 2. Sago.
(fruit juice 150 ml, water 50 ml, sago 20 g, sugar 15 g).
Dinner. Potato, poached egg, apple compote.
(potato 300 g, 1 small egg, butter 20 g, tomato 20 g,;
apple 100 g, sugar 10 g, cream 20 g).
Lunch. Toast, butter, cream, coffee or tea.
(low-protein toast 40 g, butter 15 g, cream 10 g,
sugar 5 g).
Supper. Rice salad, bread, butter, tea.
(rice 20 g, onion 10 g, carrot 30 g, mushroom 40 g,
mayonnaise 30 g, lemon juice 5 g; low-protein
bread 60 g, butter 20 g, sugar 15 g.)
Energy 2336 kcal/9782 kJ; protein – 24 g, fat – 115 g,
carbohydrates – 293 g, sodium – 1.65 g, potassium –
2.36 g, calcium – 0.19 g, phosphorus – 0.48 g.
Day 2
Breakfast 1. Bread, butter, honey, marmalade, coffee.
(low-protein bread 80 g, butter 20, marmalade 20 g,
honey 15 g, cream 10 ml, sugar 10 g).
Breakfast 2. Bread, butter, cheese, cucumber, tea.
(low-protein bread 40 g,, butter 10 g, cheese 10 g,
cucumber 30 g, sugar 5 g).
Dinner. Potato dumplings, plum compote.
(potato 250 g, 1 small egg, potato stretch 40 g,
butter 30 g; plum compote 150 g).
Lunch. Cream cocktail.
(orange juice 80 ml, cream 30 g, sugar 20 g,
vegetable oil 5 g).
Supper. Green salad, low-protein bread, butter, tea..
(potato 100 g, vegetable oil 15 g, lard 10 g, onion
20 g, ½ egg, green salad 30 g,; low-protein
bread 40 g, butter 10 g, sugar 15 g.)
Energy 2457 kcal/10,283 kJ; protein – 25 g, fat – 124 g,
carbohydrates – 297 g, sodium – 1.49 g, potassium –
2.3 g, calcium – 0.25 g, phosphorus – 0.5 g.
Day 3
Breakfast 1. Bread, butter, honey, marmalade, coffee.
(low-protein bread 80 g, butter 20, marmalade 20 g,
honey 10 g, cream 10 ml, sugar 10 g).
Breakfast 2. Bread, lard with onion, red beet, tea.
(low-protein bread 40 g, lard 15 g, onion 5 g, red
beet 30 g, sugar 10 g).
Dinner. Potato, omelet, cauliflower, raspberry compote.
(potato 250 g, 1 small egg, vegetable oil 10 ml,
cauliflower 100 g, butter 15 g, potato stretch
10 g, raspberry compote 150 ml).
Lunch. Toast, butter, cream, coffee or tea.
(low-protein toast 40 g, butter 15 g, cream 10 g,
sugar 5 g).
Supper. Bread, butter, sausage, orange, tea.
(low-protein bread 40 g, butter 20 g, sausage 10 g,
orange 120 g, sugar 10 g).
Energy 2458 kcal/10,285 kJ; protein – 25 g, fat – 130 g,
carbohydrates – 285 g, sodium – 1.545 g, potassium –
2.26 g, calcium – 0.24 g, phosphorus – 0.43 g.
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